✨ Health and Medicines Notices
NEW ZEALAND GAZETTE, No. 195
18 DECEMBER 2008
Medicines Act 1981
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Children’s Claratyne
Active Ingredient: Loratadine 5mg
Dosage Form: Chewable tablet
New Zealand Sponsor: Schering-Plough a division of Schering-Plough Animal Health Limited
Manufacturers: Schering Corporation (USA), Kenilworth, New Jersey, United States of America
Product: Nurofen Zavance Caplets (General Sale)
Active Ingredient: Ibuprofen sodium dihydrate 256mg equivalent to Ibuprofen 200mg
Dosage Form: Coated tablet
New Zealand Sponsor: Reckitt Benckiser (New Zealand) Limited
Manufacturer: Reckitt Benckiser Healthcare International Limited, Nottingham, Nottinghamshire, United Kingdom
Product: Nurofen Zavance Caplets (Pharmacy Only)
Active Ingredient: Ibuprofen sodium dihydrate 256mg equivalent to Ibuprofen 200mg
Dosage Form: Coated tablet
New Zealand Sponsor: Reckitt Benckiser (New Zealand) Limited
Manufacturer: Reckitt Benckiser Healthcare International Limited, Nottingham, Nottinghamshire, United Kingdom
Product: Nurofen Zavance Tablets (General Sale)
Active Ingredient: Ibuprofen sodium dihydrate 256mg equivalent to Ibuprofen 200mg
Dosage Form: Coated tablet
New Zealand Sponsor: Reckitt Benckiser (New Zealand) Limited
Manufacturer: Reckitt Benckiser Healthcare International Limited, Nottingham, Nottinghamshire, United Kingdom
Product: Nurofen Zavance Tablets (Pharmacy Only)
Active Ingredient: Ibuprofen sodium dihydrate 256mg equivalent to Ibuprofen 200mg
Dosage Form: Coated tablet
New Zealand Sponsor: Reckitt Benckiser (New Zealand) Limited
Manufacturer: Reckitt Benckiser Healthcare International Limited, Nottingham, Nottinghamshire, United Kingdom
Product: Spiriva Respimat
Active Ingredient: Tiotropium bromide monohydrate 3.125μg/dose equivalent to Tiotropium 2.5μg/dose
Dosage Form: Solution for inhalation
New Zealand Sponsor: Boehringer Ingelheim (NZ) Ltd
Manufacturer: Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
Dated this 12th day of December 2008.
MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
Mental Health (Compulsory Assessment and Treatment) Act 1992
Mental Health (Compulsory Assessment and Treatment) Act Notice 2008—Appointment of Director of Area Mental Health Services
Pursuant to section 92 of the Mental Health (Compulsory Assessment and Treatment) Act 1992, I, Stephen Bruce McKernan, Director-General of Health, give the following notice.
Notice
- This notice shall be read together with the Mental Health (Compulsory Assessment and Treatment) Act Notice
2000—Appointment of Directors of Area Mental Health Services (“the principal notice”)*.
- The Schedule to the principal notice is amended in respect of
"Area 7—Waikato"
by adding the name and title
"Dr Rees Tapsell, consultant psychiatrist, of Waikato."
Dated at Wellington this 9th day of December 2008.
STEPHEN BRUCE MCKERNAN, Director-General of Health.
*New Zealand Gazette, 31 August 2000, No. 117, page 2963
Next Page →
✨ LLM interpretation of page content
🏥 Consent to Distribution of New Medicines under Medicines Act 1981
🏥 Health & Social Welfare12 December 2008
Medicines, Distribution, Loratadine, Ibuprofen, Tiotropium
- MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate
🏥 Appointment of Director of Area Mental Health Services
🏥 Health & Social Welfare9 December 2008
Mental Health, Director Appointment, Waikato
- Rees Tapsell (Dr), Appointed Director of Area Mental Health Services
- STEPHEN BRUCE MCKERNAN, Director-General of Health
NZ Gazette 2008, No 195